Pharm TG SRL
2.0 FTEPharm TG reported total assets of €1.01m at the end of the 2025 financial year (annual accounts filed with the NBB on 08 Sep 2026), with 2 full-time equivalents.
The score of Pharm TG shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +139 % Total assets -11 % Headcount (avg FTE) +100 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharm TG's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 Sep 2026
- Year ended 31 Dec 2024filed on 19 Sep 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 01 Sep 2023
- Year ended 31 Dec 2021filed on 14 Oct 2022
Pharm TG's financial analysis
- Solvency14.8%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharm TG
Pharm TG's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0775.535.190
- VAT number
- BE0775535190
- Peppol
- Registered · 0208:0775535190 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 08 Oct 2021
- Registered office
- 5060 Sambreville
- Size
- Micro · 2.0 FTE
- Latest accounts
- 2025 · filed on 08 Sep 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharm TG (SRL) has been based in Sambreville since 2021, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 1,577 € and equity of 149,752 €; its revenue is not published. With 2.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 14.8%, below the median of its sector (41.5%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Pharm TG
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Smits Europe Retail sale of pharmaceutical products Wavre · balance sheet €1.01m
- Apotheek Ilse Caudron Retail sale of pharmaceutical products Aalst · balance sheet €1.01m
- Smeets Tom Retail sale of pharmaceutical products Lint · balance sheet €1.01m
- Valophar Retail sale of pharmaceutical products Gembloux · balance sheet €1.02m
- Wezefarma Retail sale of pharmaceutical products Rotselaar · balance sheet €1.01m
- Pharmapoint Retail sale of pharmaceutical products Maasmechelen · balance sheet €1.02m
- Pharma Link Retail sale of pharmaceutical products Lichtervelde · balance sheet €1.02m
- Distephar Retail sale of pharmaceutical products Zedelgem · balance sheet €1.01m
Frequently asked questions about Pharm TG
What is the revenue of Pharm TG?
Pharm TG files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharm TG?
In Belgium, the VAT number is the company number prefixed with BE: BE0775535190 for Pharm TG, if the company is VAT-registered. Its company number (CBE) is 0775.535.190.
Where is the registered office of Pharm TG?
According to the CBE register, the registered office of Pharm TG is in 5060 Sambreville.
What is the equity of Pharm TG?
At the close of the 2025 financial year, the equity of Pharm TG amounts to 149,752 €, a solvency of 14.8% of total assets.
How many people work at Pharm TG?
2.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharm TG?
The register lists 1 active mandates at Pharm TG. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharm TG
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →